ABBOTINDIA - IntraDay Trade Analysis with Live Signals

Last Updated Time : 20 Dec 25, 07:02 am

IntraDay Trade Rating: 3.6

📊 Analysis: ABBOTINDIA is trading below both its 50 DMA (₹29,321) and 200 DMA (₹30,233), showing short-term weakness. RSI at 37.0 indicates oversold conditions, while MACD negative (-498) confirms bearish bias. Current volume is slightly above the 1-week average, suggesting moderate participation. Fundamentals remain strong with ROCE (46.2%), ROE (35.7%), and EPS of ₹710, but technicals limit intraday attractiveness.

💡 Optimal Buy Price: Around ₹27,800–₹28,100 (near support zone).

🎯 Profit-Taking Exit Levels: ₹28,400 (first resistance), ₹28,800 (next resistance).

🛡️ Stop-Loss / Loss Protection: ₹27,600 (below immediate support).

⏱️ If Already Holding: Consider exiting intraday if price fails to sustain above ₹28,000 with RSI dropping below 36 or MACD widening negatively. If price rebounds with volume and crosses ₹28,400, hold for extended profit up to ₹28,800.

✅ Positive

• 📈 Strong ROCE (46.2%) and ROE (35.7%) indicate excellent efficiency.
• 📊 EPS of ₹710 shows robust earnings power.
• 💰 Very low debt-to-equity ratio (0.05).
• 📈 Dividend yield at 1.70% provides income support.

⚠️ Limitation

• 📉 Trading below both 50 DMA and 200 DMA.
• 📊 RSI at 37.0 indicates oversold but weak momentum.
• 📉 MACD negative (-498), showing strong bearish bias.

🚨 Company Negative News

• 📉 DII holdings reduced (-0.07%).

🌟 Company Positive News

• 📈 PAT improved from ₹366 Cr. to ₹415 Cr. sequentially (+15.8%).
• 📊 Stable FII holdings (0.00%).

🏭 Industry

• 📊 Industry PE at 30.6, lower than ABBOTINDIA’s 39.4, showing relative overvaluation.
• 📈 Sector strength moderate with 52-week index at 23.3%.

📌 Conclusion

⚖️ ABBOTINDIA is a moderate intraday candidate with strong fundamentals but weak technical momentum. Suitable for cautious trades near support levels with tight stop-loss. Profit-taking should be considered at ₹28,400–₹28,800, while risk management is critical due to bearish technical indicators.

Would you like me to extend this into a peer benchmarking overlay comparing ABBOTINDIA against other pharma and healthcare stocks for intraday confirmation?